The Standard Metabolic Reporting Structures working group: John C Lindon1, Jeremy K Nicholson1, Elaine Holmes1, Hector C Keun1, Andrew Craig1, Jake T M Pearce1, Stephen J Bruce1, Nigel Hardy2, Susanna-Assunta Sansone3, Henrik Antti4, Par Jonsson4, Clare Daykin5, Mahendra Navarange6, Richard D Beger7, Elwin R Verheij8, Alexander Amberg9, Dorrit Baunsgaard10, Glenn H Cantor11, Lois Lehman-McKeeman11, Mark Earll12, Svante Wold13, Erik Johansson13, John N Haselden14, Kerstin Kramer15, Craig Thomas16, Johann Lindberg17, Ina Schuppe-Koistinen17, Ian D Wilson18, Michael D Reily19, Donald G Robertson19, Hans Senn20, Arno Krotzky21, Sunil Kochhar22, Jonathan Powell23, Frans van der Ouderaa23, Robert Plumb24, Hartmut Schaefer25
& Manfred Spraul251
Biological Chemistry, Biomedical Sciences Division, Imperial College London, Sir Alexander Fleming Building, South Kensington, London SW7 2AZ, UK.
2
Department of Computer Science, University of Wales, Aberystwyth, SY23 3DB, UK.
3
The European Bioinformatics Institute, EMBL Outstation, Wellcome Trust Genome Campus, Hinxton, Cambridge, CB10 1SD, UK.
4
Research Group for Chemometrics, University of Umeå, SE-901 87 Umeå, Sweden.
5
Centre for Analytical Biosciences, School of Pharmacy, University of Nottingham, University Park, Nottingham NG7 2RD, UK.
6
MRC Clinical Sciences Centre, Faculty of Medicine, Imperial College London, Hammersmith Hospital Campus, Du Cane Road, London W12 0NN, UK.
7
Center for Metabolomics, Division of Systems Toxicology, National Center for Toxicological Research, Food and Drug Administration, Jefferson, Arkansas 72079, USA.
8
TNO Pharma, Utrechtseweg 48, PO Box 360, 3700AJ Zeist, The Netherlands.
9
Sanofi-Aventis, Drug Safety Evaluation, Mainzer Landstrasse 50, 65795 Hattersheim, Germany.
10
NovoNordisk A/S, Novo Nordisk Park DK-2760 Måløv, Denmark.
11
Bristol-Myers Squibb, PO Box 5400, Princeton, New Jersey 08543, USA.
12
Umetrics UK Ltd., Woodside House, Woodside Road, Winkfield, Windsor, SL4 2DX, UK.
13
Umetrics, Tvistevägen, 48 Box 7960, SE-907 19 Umeå, Sweden.
14
Safety Assessment, GlaxoSmithKline, Park Road, Ware, Hertfordshire, SG12 0DP, UK.
15
Department of Toxicology and Drug Disposition, Lilly Development Centre, Parc Scientifique de Louvain-la-Neuve, Rue Granbonpre 11, B-1348, Mont-Saint-Guibert, Belgium.
16
Investigative Toxicology, Lilly Research Laboratories, 2001 W. Main St., Greenfield, Indiana 46140, USA.
17
Molecular Toxicology, Safety Assessment, AstraZeneca, Södertälje, Sweden.
18
Department of Drug Metabolism and Pharmacokinetics, AstraZeneca, Mereside, Alderley Park, Macclesfield, Cheshire SK10 4TG, UK.
19
Pfizer Global R&D, 2800 Plymouth Road, Ann Arbor, Michigan 48105, USA.
20
Hoffmann LaRoche AG, Department for Biostructural Research, Grenzacher Str., CH-4070 Basel, Switzerland.
21
Metanomics GmbH & Co. KGaA, Tegeler Weg 33, 10589 Berlin, Germany.
22
Nestle Research Center, BioAnalytical Science, CH-1000 Lausanne 26, Switzerland.
23
Corporate Research, Unilever Research Laboratory, Colworth, Sharnbrook, Bedford, MK44 1LQ, UK.
24
Waters Life Sciences R&D Group, 34 Maple Street, Milford, Massachusetts 01757, USA.
25
Bruker BioSpin GmbH, Silberstreifen 4, 76287 Rheinstetten, Germany.
Correspondence should be addressed to John C Lindon j.lindon@imperial.ac.uk
